These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 31960724)

  • 1. Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.
    Welty M; Mesana L; Padhiar A; Naessens D; Diels J; van Sanden S; Pacou M
    Curr Med Res Opin; 2020 Apr; 36(4):595-606. PubMed ID: 31960724
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis.
    Lu X; Jarrett J; Sadler S; Tan M; Dennis J; Jairath V
    Int J Clin Pharm; 2023 Apr; 45(2):330-341. PubMed ID: 36484968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.
    Singh S; Murad MH; Fumery M; Dulai PS; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2179-2191.e6. PubMed ID: 31945470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons.
    Reinisch W; Melmed GY; Nakase H; Seidelin J; Ma C; Xuan S; Tran J; Remple V; Wegrzyn L; Levy G; Sanchez Gonzalez Y; Panaccione R
    Adv Ther; 2024 Oct; 41(10):3832-3849. PubMed ID: 39126596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.
    Jairath V; Chan K; Lasch K; Keeping S; Agboton C; Blake A; Patel H
    Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):711-722. PubMed ID: 33599181
    [No Abstract]   [Full Text] [Related]  

  • 7. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
    Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
    Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
    Sardesai A; Dignass A; Quon P; Milev S; Cappelleri JC; Kisser A; Modesto I; Sharma PP
    J Med Econ; 2021; 24(1):279-290. PubMed ID: 33502905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis.
    Lu X; Zhou ZY; Xin Y; Wang MJ; Gray E; Jairath V; Lindsay JO
    Inflamm Bowel Dis; 2024 Jan; 30(1):64-77. PubMed ID: 36946138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparative efficacy and safety of biologics and small molecules for treating patients with ulcerative colitis in Portugal: a systematic literature review and network meta-analysis.
    Sanchez Gonzalez Y; Prata R; Alves D
    Eur Rev Med Pharmacol Sci; 2023 Jul; 27(14):6744-6759. PubMed ID: 37522686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis.
    Vickers AD; Ainsworth C; Mody R; Bergman A; Ling CS; Medjedovic J; Smyth M
    PLoS One; 2016; 11(10):e0165435. PubMed ID: 27776175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world effectiveness of ustekinumab and vedolizumab in TNF-exposed pediatric patients with ulcerative colitis.
    Patel PV; Zhang A; Bhasuran B; Ravindranath VG; Heyman MB; Verstraete SG; Butte AJ; Rosen MJ; Rudrapatna VA;
    J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1126-1134. PubMed ID: 38482890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Speed of Early Symptomatic Remission With Advanced Therapies for Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.
    Ahuja D; Murad MH; Ma C; Jairath V; Singh S
    Am J Gastroenterol; 2023 Sep; 118(9):1618-1625. PubMed ID: 36976548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
    Kobayashi T; Hoshi M; Yuasa A; Arai S; Ikeda M; Matsuda H; Kim SW; Hibi T
    Pharmacoeconomics; 2023 May; 41(5):589-604. PubMed ID: 36884164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
    Cholapranee A; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2017 May; 45(10):1291-1302. PubMed ID: 28326566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis.
    Hibi T; Kamae I; Pinton P; Ursos L; Iwakiri R; Hather G; Patel H
    Intest Res; 2021 Jan; 19(1):53-61. PubMed ID: 32312035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.
    Singh S; Fumery M; Sandborn WJ; Murad MH
    Aliment Pharmacol Ther; 2018 Jan; 47(2):162-175. PubMed ID: 29205406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment sequence network meta-analysis in Crohn's disease: a methodological case study.
    Varu A; Wilson FR; Dyrda P; Hazel M; Hutton B; Cameron C
    Curr Med Res Opin; 2019 May; 35(5):733-756. PubMed ID: 30727745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab.
    Favale A; Onali S; Caprioli F; Pugliese D; Armuzzi A; Macaluso FS; Orlando A; Viola A; Fries W; Rispo A; Castiglione F; Mocci G; Chicco F; Usai P; Calabrese E; Biancone L; Monteleone G; Fantini MC;
    Inflamm Bowel Dis; 2019 Oct; 25(11):1805-1812. PubMed ID: 30931477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
    Thorlund K; Druyts E; Toor K; Mills EJ
    Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.